T1DCRN awards nearly $4 million in new funding for the next generation of type 1 diabetes research

Minister Simon Birmingham has announced that nearly $4 million has been awarded to Australian researchers for the Type 1 Diabetes Clinical Research Network (T1DCRN) Australasian Diabetes Data Network (ADDN) and Career Development Awards.

ADDN is receiving a $2 million funding boost to extend the database beyond the current 6,000 young people, which will give researchers unprecedented ability to gain a national understanding of the incidence, development and management of T1D.

The database was established in 2012 to give researchers access for the first time to national level information about T1D. The new funding will extend the reach of the T1D database to include regional Australia, as well as the age range to include adults with T1D.

JDRF Australia CEO Mike Wilson said the Australasian Diabetes Data Network helps researchers identify people with T1D who are eligible for clinical trials, which in turn makes it easier for patients to access new therapies and treatments.

He said the funding would also allow for formal links to be forged with similar registries around the world. “JDRF Australia is in talks with similar groups in the US and Germany, and this is where we add value. Global vision is what’s needed to really accelerate research progress for T1D,” Mr Wilson said.

The Career Development Awards (CDAs) will provide crucial support to build the next generation of innovative leaders in type 1 diabetes research. Each CDA provides salary and research project funding for exceptional researchers who propose highly innovative clinical research that has the potential to transform existing paradigms in preventing, treating or curing type 1 diabetes.

CDA Awardees must be within fifteen years of receiving their PhD or equivalent and should demonstrate a promising track record of achievements appropriate to their career stage. The Award will help them to become established as future leaders in the field.

This Award also provides a new and ground-breaking benefit, leadership training. The goal is to create a new generation of leaders who will be coached to maximize their impact, add value across the sector, mentor emerging researchers and accelerate patient access to their research.

“The Network’s Career Development Awards provide crucial salary and project support to emerging innovative research leaders in type 1 diabetes,” Minister Birmingham said. “It is world-leading research like this that the Turnbull Government wants to promote as part of the ideas boom.”

Dr Dorota Pawlak, Director of the T1DCRN and Head of Research Development at JDRF said this Award would deliver on the principal goal of the T1DCRN, which is to positively impact the lives of people with type 1 diabetes.

“With a strong focus on innovation in clinical research, this Award will deliver benefits to the T1D community, and invest in high-achieving researchers who are the future leaders of T1D research.”

Career Development Awardees:

A/Prof Melinda Coughlan, Baker IDI. ‘Mapping the mitochondrial signature of individuals with type 1 diabetes and nephropathy’
Associate Professor Melinda Coughlan has a BSc Honours in Nutrition from Deakin University, and PhD in Obstetrics & Gynaecology from the University of Melbourne. She currently holds research grants from the NHMRC and JDRF and holds a dual appointment as Adjunct Associate Professor in Monash University’s Department of Medicine, Central Clinical School and the Department of Epidemiology & Preventive Medicine. A/Prof. Coughlan has over 40 publications in highly respected journals.

Associate Professor Anand Hardikar from the University of Sydney. ‘PREDICT T1D: Plasma RNA Evaluation and Diagnosis In Children progressing To Type 1 Diabetes’
Anandwardhan A. Hardikar, PhD, received MSc in Zoology (Genetics) and a PhD in Zoology from the University of Pune. After successful completion of his PhD work, he continued training in the field of pancreas biology and diabetes at the University of Pennsylvania, School of Medicine. Associate Professor Hardikar lead Diabetes and Pancreas Biology Section at O’Brien Institute, St. Vincent’s Hospital and the University of Melbourne, in Melbourne, Australia. He is currently an Associate Professor and Australian Future Fellow (ARC) at the NHMRC Clinical Trials Centre, Sydney Medical School.

The T1DCRN is supported by the Australian Government through the Special Research Initiative for Type 1 Juvenile Diabetes, a $35 million grant funded by the Australian Research Council.

Read the media release.

Find out more about ADDN.

Find out more about T1DCRN clinical research projects.

Common virus increases activity of T1D-risk genes in pancreatic islets


Image credit: University of Pennsylvania

Infection with a common virus known as coxsackievirus B has long been thought to be associated with the development of type 1 diabetes. Now, researchers have published evidence that this virus could be driving the activity of the very genes that increase the risk of developing type 1 diabetes.  Read More

Early probiotic use could help prevent type 1 diabetes in at-risk children

Giving probiotics to babies in the first few weeks of life may lower their risk of developing type 1 diabetes, a recent study has found.


The study, published in JAMA Pediatrics found that children who were given probiotics within the first 27 days of life had a 60% reduction in the risk of developing islet autoimmunity, compared with children who were first given probiotics after 27 days or not at all. Read More

Sanofi and Lexicon Pharmaceuticals partner on new non-insulin therapy for type 1 diabetes

JDRF partner Sanofi and Lexicon Pharmaceuticals have announced a new collaboration to develop and commercialise a new oral drug for the treatment of type 1 diabetes.

Nadav Kidron, CEO of Oramed Pharmaceuticals, poses for a photo in Jerusalem

The drug is called sotagliflozin and is used in conjunction with insulin to help improve blood glucose levels by blocking glucose absorption in the kidneys and the gut.  Read More

World first trial to slow type 1 diabetes development in children

The Australian Type 1 Diabetes Clinical Research Network has partnered with the Immune Tolerance Network to launch a new Australian clinical trial to slow the development of newly diagnosed type 1 diabetes in children.


The EXTEND-P trial is expected to begin recruitment in March 2016 to test the ability of an existing drug called tocilizumab to preserve beta cell function. Tocilizumab, sold under the brand name Actemra, is currently approved for use in children with juvenile arthritis. Read More

T1DCRN awards $14 million for type 1 diabetes clinical research

The Type 1 Diabetes Clinical Research Network (T1DCRN) announced today that over $14 million in grants have been awarded to Australian researchers for clinical research projects commencing in 2016.

RFA1 Announcement 090915

This funding forms part of the $35 million funding awarded to the T1DCRN by the Australian Research Council, and will support five innovative programs targeting a broad range of T1D research areas including: Read More

Innovative biodegradable scaffold protects transplanted islets

A new technique that could drastically improve outcomes of human islet transplantation has been successful in a world-first clinical trial.

BioHub scaffold

The technique, developed by the US-based Diabetes Research Institute (DRI) and supported in part by JDRF funding, involves transplanting islets in a biodegradable ‘scaffold’ into the omentum, a fold of tissue that covers and protects the abdominal organs. Read More

Psoriasis drug may halt the destruction of beta cells in T1D

People with type 1 diabetes (T1D) may be able to preserve their remaining beta cells with alefacept, a drug normally used for psoriasis.


A recent clinical trial has shown that alefacept was able to slow or halt the progression of beta cell destruction in people newly diagnosed with T1D, even two years after completing treatment. Read More

Phase II clinical trial of common vaccine to reverse type 1 diabetes

A commonly used vaccine has received FDA approval for a Phase II clinical trial to test its ability to reverse long-standing type 1 diabetes. The announcement was made at the 75th Scientific Sessions of the American Diabetes Association (ADA) by Associate Professor Denise Faustman from Massachusetts General Hospital.


The vaccine is known as bacillus Calmette-Guérin (BCG), and has been used for over 90 years as a vaccine for tuberculosis, and more recently as a treatment for bladder cancer. A 2012 pilot study in adults with long standing type 1 diabetes showed that two injections of BCG spaced 4 weeks apart temporarily reduced the number of auto-reactive killer T cells and increased the number of beneficial regulatory T cells. The vaccine was able to transiently increase the amount of c-peptide in the blood, indicating some restoration of islet function and insulin secretion. Read More